ALXO (ALX Oncology Holdings) PB Ratio: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALXO ALX Oncology Holdings Inc ALXO
31 GF Score
Price $2.01
! 3 Warning Signs
View Full Analysis

What is ALX Oncology Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-25), ALX Oncology Holdings's share price is $2.005. ALX Oncology Holdings's Book Value per Share for the quarter that ended in Jun. 2026 was $-5.49. Hence, ALX Oncology Holdings's PB Ratio of today is .

The historical rank and industry rank for ALX Oncology Holdings's PB Ratio or its related term are showing as below:

During the past 8 years, ALX Oncology Holdings's highest PB Ratio was 13.05. The lowest was 0.04. And the median was 0.77.

ALXO's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.955
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, ALX Oncology Holdings's average Book Value Per Share Growth Rate was -555.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -58.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -44.20% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of ALX Oncology Holdings was -29.40% per year. The lowest was -58.00% per year. And the median was -37.90% per year.

Back to Basics: PB Ratio


ALX Oncology Holdings  (NAS:ALXO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


ALX Oncology Holdings PB Ratio Related Terms


ALX Oncology Holdings PB Ratio Historical Data

* Premium members only.

The historical data trend for ALX Oncology Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ALX Oncology Holdings PB Ratio Chart

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial 2.40 1.75 3.92 0.78 2.36

ALX Oncology Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 2.19 2.36 0.00 0.00

ALXO vs CYDY, BCYC, ELDN: PB Ratio Comparison

For the Biotechnology subindustry, ALX Oncology Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ALX Oncology Holdings PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's PB Ratio falls into.


ALXO
31GF Score
ALX Oncology Holdings Inc ALXO
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ALX Oncology Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

ALX Oncology Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=2.005/-5.489
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


ALX Oncology Holdings Business Description

Address 323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score

Get the complete analysis for ALXO

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.01
Price